In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on Amgen (AMGN – Research Report), with a price target of $328.00. The company’s shares closed yesterday at $278.39.
Renza covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Amgen, and Exelixis. According to TipRanks, Renza has an average return of 18.3% and a 46.06% success rate on recommended stocks.
In addition to RBC Capital, Amgen also received a Buy from William Blair’s Matt Phipps in a report issued today. However, on the same day, Barclays upgraded Amgen (NASDAQ: AMGN) to a Hold.
The company has a one-year high of $327.16 and a one-year low of $206.75. Currently, Amgen has an average volume of 2.92M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amgen (AMGN) Company Description:
Founded in 1980, California-based Amgen, Inc. is one of the world’s leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
Read More on AMGN:
- AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
- Options Volatility and Implied Earnings Moves Today, May 02, 2024
- BMO sees CytomX rallying after ‘surprise’ data announcement
- Amgen settlement with Sandoz a positive, says Jefferies
- Sandoz, Amgen to resolve all patent disputes relating to denosumab biosimilars
